Gattex (teduglutide) / Takeda - LARVOL DELTA

Complications of IPEX Syndrome with Crohn’s-Like Enterocolonopathy Resulting in Short Gut Syndrome (ACG 2024) - "His symptoms improved with bowel rest and IV fluids, and he was discharged with teduglutide and outpatient follow up with GI and general surgery...A multidisciplinary team of surgery, gastroenterology, and nutrition should be closely following these patients to prevent potentially severe complications of short gut syndrome. Figure: Transition point seen proximal to the midline ileostomy, suggesting possible ileus versus SBO."

Atopic Dermatitis • Crohn's disease • Dermatology • Diabetes • Endocrine Disorders • Gastroenterology • Immunology • Metabolic Disorders • Pain • Short Bowel Syndrome • FOXP3

Optimizing peripubertal growth in a child with short bowel syndrome on full oral feeding with glucagon-like peptide 2 analog. (PubMed, JPGN Rep) - "Teduglutide is a glucagon-like peptide 2 (GLP-2) analog which acts by increasing intestinal absorption of the remnant bowel for children with short bowel syndrome (SBS) dependent on parenteral nutrition...Pubertal spurt might be impaired in children with SBS on full oral feeding if the caloric need is not met by the residual intestinal absorption rate. GLP-2 analog might represent an option to sustain pubertal spurt in SBS children on full oral feeding with hyperphagia."

Journal • Gastrointestinal Disorder • Inflammatory Bowel Disease • Short Bowel Syndrome

LONG-TERM SAFETY AND EFFECTIVENESS OF TEDUGLUTIDE IN PAEDIATRIC PATIENTS WITH SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE: AN OBSERVATIONAL, PROSPECTIVE, MULTICENTRE REGISTRY (UEGW 2024) - "Full abstracts will be published on 21 September 2024"

Clinical • Observational data • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

TEDUGLUTIDE REVERSES INTESTINAL FAILURE IN PERCC1-ASSOCIATED ENTEROPATHY- A CASE REPORT (UEGW 2024) - "Full abstracts will be published on 21 September 2024"

Case report • Clinical • Gastrointestinal Cancer • Oncology

TEDUGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME IN CROHN'S DISEASE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS (UEGW 2024) - "Full abstracts will be published on 21 September 2024"

Retrospective data • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

ENDOSCOPIC SMALL BOWEL SURVEILLANCE IN PATIENTS WITH SHORT BOWEL SYNDROME IN TREATMENT WITH TEDUGLUTIDE (UEGW 2024) - "Full abstracts will be published on 21 September 2024"

Clinical • Gastrointestinal Disorder • Short Bowel Syndrome

Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry. (PubMed, Nutrients) - P=N/A | "Overall, ever-treated and never-treated patients had similar baseline characteristics. Differences between treatment groups may reflect variations in patient selection and degree of monitoring."

Journal • Colonic Polyps • Colorectal Cancer • Crohn's disease • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Short Bowel Syndrome • Solid Tumor

Management of Short Bowel Syndrome With Chronic Intestinal Failure: A Single-Center Experience in Portugal. (PubMed, Cureus) - "Two patients recently started teduglutide with good tolerance and need a reduction in HPN support...The existence of the commitment and interest of professionals involved in SBS/CIF at Centro Hospitalar Universitário de Santo António, Portugal, was a fundamental key to achieving those results. A multidisciplinary healthcare group for HPN support can be essential to ensuring these patients' survival and quality of life."

Journal • Cardiovascular • Congestive Heart Failure • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Septic Shock • Short Bowel Syndrome • Thrombosis

Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease. (PubMed, Small) - "Upon oral administration to colitis-induced mice, ROS-sensitive NPs are located in the colon, displaying healing capacity and reducing inflammation. Cleavable PEGylated NPs demonstrate effective potential in managing IBD symptoms and modulating the disease's progression."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Intestinal adaptation and rehabilitation in adults with short bowel syndrome. (PubMed, Curr Opin Clin Nutr Metab Care) - "Real-world data confirmed the teduglutide efficacy not only in weaning off IVS in accurately selected patients but also increased the alert on the risk of development of gastrointestinal polyps related to the drug; the impact of the therapy on patients' QoL deserves further studies and the cost-utility of the treatment is still uncertain. Some case reports highlighted the potential benefit of treatment with teduglutide in non-SBS gastrointestinal diseases, such as graft-versus-host disease, primary amyloidosis and refractory microscopic colitis. Phase 2 RCTs on safety and efficacy of two new long-acting GLP-2 analogues, glepaglutide and apraglutide, were published, and phase 3 RCTs have been completed."

Journal • Amyloidosis • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Short Bowel Syndrome

Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure. (PubMed, J Pediatr Gastroenterol Nutr) - P3 | "In pediatric patients with SBS-IF, teduglutide treatment resulted in long-term reductions in PN/IV requirements. The degree of PN/IV volume reduction depended on the duration of teduglutide exposure, underlying bowel anatomy, and demographics."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

PREDICTORS OF RESPONSE TO GLUCAGON-LIKE PEPTIDE 2 IN CHILDREN WITH SHORT BOWEL SYNDROME (ESPGHAN 2024) - "Female patients with better nutritional status are more likely to respond to teduglutide after 6 months. Liver dysfunction at diagnosis negatively influence 12-months treatment response. Monitoring hemoglobin and citrulline in the first 6 months might help to foresee treatment response."

Clinical • Gastrointestinal Disorder • Hepatology • Liver Failure • Short Bowel Syndrome

RECURRENT ENCEPHALOPATHY AND SEVERE METABOLIC ACIDOSIS IN A PATIENT WITH SHORT BOWEL: THINK D-LACTIC ACIDOSIS (ESPGHAN 2024) - "Began teduglutide therapy in June/2021, started to wean-off TPN, which was discontinued in August/2022, stopped teduglutide in January/2023.In August/2023, during vacation in Sardinia, high temperatures and a pasta based diet, he began episodes of vomiting and periods of altered consciousness.Observed in the local hospital with a severe metabolic acidosis...Daily TPN was restarted, with a one-week fasting period and intestinal decontamination with rifaximin, resulting in progressive improvement... Our case shows that D-lactate encephalopathy should be suspected and serum D-lactate measured whenever neurological symptoms occur in a patient with SBS. As D-lactic acid is not detected by conventional laboratory techniques, special laboratory tests must be performed when D-LA is suspected."

Clinical • CNS Disorders • Gastrointestinal Disorder • Metabolic Disorders • Rare Diseases • Short Bowel Syndrome

TEDUGLUTIDE USE IN ENGLAND OUTSIDE CLINICAL TRIALS - SINGLE CENTRE EXPERIENCE (ESPGHAN 2024) - "Teduglutide appears safe and effective in reducing PN requirements in paediatric patients but more data is needed to understand it´s long term efficacy and results after discontinuation."

Clinical • Gastrointestinal Disorder • Metabolic Disorders • Pain • Pediatrics • Rare Diseases • Short Bowel Syndrome

EXPERIENCE OF TEDUGLUTIDE IN CHILDREN WITH SHORT BOWEL SYNDROME: CASE SERIES (ESPGHAN 2024) - "Ted is a safe and well-tolerated drug for children affected by SBS. Drug-related adverse events in our patients were infrequent, only headaches, and none resulted in drug discontinuation. Ted appears to reduce PN dependence, resulting in a real improvement in the quality of life and encouraging treatment adherence."

Clinical • Contact Dermatitis • Gastrointestinal Disorder • Pain • Pediatrics • Short Bowel Syndrome

LONG-TERM TEDUGLUTIDE TREATMENT IN CHILDREN WITH SHORT BOWEL SYNDROME: A REAL-LIFE, MULTICENTER, RETROSPECTIVE STUDY OF PATIENTS TREATED FOR MORE THAN 1 YEAR (ESPGHAN 2024) - "Long-term teduglutide in children with SBS-IF resulted in a sustained, and safe reduction in PN dependency. Further studies are required to evaluate the proportion of patients acquiring or losing response after one year, providing crucial insights into the durability and dynamics of teduglutide response over an extended period."

Retrospective data • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

REAL-LIFE EXPERIENCE OF TEDUGLUTIDE USE IN PEDIATRIC PATIENTS WITH SHORT BOWEL SYNDROME IN ARGENTINA (ESPGHAN 2024) - "TED offers a new dimension in the treatment of CIF allowing significant PN reduction, improving the chances of achieving intestinal adaptation."

Clinical • Gastrointestinal Disorder • Metabolic Disorders • Pain • Pediatrics • Rare Diseases • Short Bowel Syndrome

A Study of Teduglutide in Japanese People With Short Bowel Syndrome (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: Takeda | Trial primary completion date: Jul 2030 ➔ Feb 2026 | Trial completion date: Jul 2030 ➔ Feb 2026

Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Short Bowel Syndrome

Cholecystitis following the initiation of glucagon-like peptide-2 analogue for short bowel syndrome: A case report. (PubMed, Nutr Clin Pract) - "Teduglutide (Revestive), a glucagon-like peptide-2 (GLP-2) analogue, is the first effective therapy approved for treating patients with SBS via self-subcutaneous injection...GLP-2 analogues promote gallbladder refilling and epithelial hyperplasia, which may be a risk factor for cholecystitis in patients with cholelithiasis, as observed in our patient. Based on our experience, patients with SBS and established asymptomatic cholelithiasis may be considered for prophylactic cholecystectomy before the administration of GLP-2 analogues."

Journal • Gastroenterology • Gastrointestinal Disorder • Hepatology • Pain • Short Bowel Syndrome

EFFICACY AND SAFETY OF TEDUGLUTIDE IN SHORT BOWEL SYNDROME IN PATIENTS OVER 70 YEARS OLD (DDW 2024) - "Teduglutide appears to be an effective treatment option for older patients with SBS. Longer-term and larger studies in this older population are needed to confirm these findings."

Clinical • Cardiovascular • Colonic Polyps • Colorectal Cancer • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease • Pulmonary Disease • Short Bowel Syndrome • Thrombosis • Venous Thromboembolism

GLP-2 PHARMACOTHERAPY ACTIVATES HEPATIC FXR-SIGNALING TO ATTENUATE RESECTION-ASSOCIATED BILE ACID LOSS IN MICE (DDW 2024) - "The data suggest that GLP- -pharmacotherapy in mice significantly slows bile acid circulation primarily via hepatic FXR signaling to alleviate resection-induced bile acid loss."

Preclinical • Gastroenterology • Gastrointestinal Disorder • Short Bowel Syndrome • CYP8B1

Emerging drugs for the treatment of short bowel syndrome. (PubMed, Expert Opin Emerg Drugs) - "Clinical trials and real-world experience demonstrated that Teduglutide   reduces dependence on parenteral support andhas a place in the management of patients with SBS-CIF.  The use of Teduglutide should be discussed inpatients stabilized after resection and its introduction requires the advice ofan expert center capable of assessing the benefit-risk ratio. The complex, individualized management of SBS-C IF requires theexpertise of a specialized IF center which a multidisciplinary approach. Thearrival of new treatments will call for new therapeutic strategies, and thequestion of how to introduce and monitor them will represent a new therapeuticchallenge."

Journal • Review • Gastrointestinal Disorder • Short Bowel Syndrome

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: Takeda | Trial completion date: Mar 2024 ➔ Jul 2024 | Trial primary completion date: Mar 2024 ➔ Jul 2024

Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Short Bowel Syndrome

Reversal of Intestinal Failure With Teduglutide in PERCC1-Associated Enteropathy: A Case Report. (PubMed, Ann Intern Med) - No abstract available

Journal

Efficacy and safety of glucagon-like peptide-2 (GLP-2) in patients with short bowel syndrome; A Systematic Review and Network Meta-analysis. (PubMed, J Gastrointest Surg) - "Despite the small number of patients in the included studies and variable follow-up duration, GLP-2 seems safe and effective in patients with SBS. GLP-2 showed a positive effect on increasing plasma citrulline level and decreasing alkaline phosphatase level."

Journal • Retrospective data • Review • Gastrointestinal Disorder • Infectious Disease • Short Bowel Syndrome